Skip to main content

Table 1 Summary of the randomized controlled trials (RCTs) included in this meta-analysis

From: Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies

Author Year Phase of the trial Duration of therapy Intervention arm-1 Intervention arm-2 Intervention arm-3 Intervention arm-4 Control arm
Kremer JM et al. study 1[18] 2012 Phase IIb 24-weeks Tofacitinib 3-mg BID + Methotrexate (N = 68) Tofacitinib 5-mg BID + Methotrexate (N = 71) Tofacitinib 10-mg BID + Methotrexate (N = 74) Tofacitinib 15-mg BID + Methotrexate (N = 75) Placebo + Methotrexate (N = 69)
Tanaka Y et al.[19] 2011 Phase II 12-weeks Tofacitinib 3-mg BID + Methotrexate (28) Tofacitinib 5-mg BID + Methotrexate (N = 28) Tofacitinib 10-mg BID + Methotrexate (N = 28) .. Placebo + Methotrexate (N = 28)
Fleischmann R et al. study 1[16] 2012 Phase IIb 24-weeks Tofacitinib 3-mg BID (N = 51) Tofacitinib 5-mg BID (N = 49) Tofacitinib 10-mg BID (N = 61) Tofacitinib 15-mg BID (N = 57) Placebo (N = 59)
Fleischmann R et al. study 2[11] 2012 Phase III 6-months .. Tofacitinib 5-mg BID (N = 243) Tofacitinib 10-mg BID (N = 245) .. Placebo (N = 122)
Kremer JM et al. study 2[17] 2009 Phase IIa 12-weeks . Tofacitinib 5-mg BID (N = 61) .. Tofacitinib 15-mg BID (N = 69) Placebo (N = 65)
Burmester GR et al.[10] 2013 Phase III 6-months Tofacitinib 5-mg BID + Methotrexate (N = 133) Tofacitinib 10-mg BID + Methotrexate (N = 134) .. Placebo + Methotrexate (N = 132)
van der Heijde D et al.[12] 2013 Phase III 24-month .. Tofacitinib 5-mg BID + Methotrexate (N = 321) Tofacitinib 10-mg BID + Methotrexate (N = 316) .. Placebo + Methotrexate (N = 160)
van Vollenhoven RF et al.[13] 2012 Phase III 12-month .. Tofacitinib 5-mg BID + Methotrexate (N = 204) Tofacitinib 10-mg BID + Methotrexate (N = 201) .. Placebo + Methotrexate (N = 108)
  1. N = Sample size.